Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Johnson & Johnson JNJ announced that the FDA has approved its supplemental new drug application (sNDA), seeking approval for ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

Rep. Mike Collins (R-Ga.) heavily criticized statements made by the Right Rev. Mariann Budde on Tuesday at the inaugural ...

They are now the most commonly prescribed antidepressant medications. They are prescribed to treat depression but are also used to treat a broader range of depressive disorders, anxiety disorders, and ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Spravato is a first-of-its-kind medication to help manage treatment-resistant depression, according to Johnson & Johnson.

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

But many people who take daily medications are unaware that certain drugs in their pill box can also increase their risk of ...

Healthcare professionals may recommend tapering off antidepressants, like Lexapro, if you experience unwanted side effects, need to switch medications, or have reached the end of a short-term ...

Kelsey Warren KWarren6@its.jnj.com  609 218 4053 Investor contact: Lauren Johnson investor-relations@its.jnj.com ...